Abstract

Meropenem is the first representative of carbapenem analogues with methyl group, which has been applied in medicine. This drug has been approved by FDA (Food and Drug Administration) in 1996. Available results of clinical trials and scientific reports point surprising synergism of combination of meropenem with other chemotherapeutics, in the treatment of bacterial diseases. Present study based on available information presents indications for use the mentioned antibiotic in pharmacotherapy of infectious diseases. Meropenem is the first representative of carbapenem analogues, which contains methyl group. Introduction of a methyl group at the system of coupled rings: β-lactam and pyrrolidine, solved the problem of degradation by the dehydropeptidase-I (DHP-I). In the consequence it is not necessary to use meropenem in the connection with specific DHP-I inhibitors. Meropenem, similarly to other carbapanem analogues, is intended for the treatment of severe inpatient and outpatient infections. Bacterial resistance to meropenem may be the result of: carbapenemases activity, decreased affinity to Penicillin Binding Proteins – PBP (mainly PBP 2 and PBP 3) and activation of efflux pump (antibiotic ejection outside the cell). Twenty-year period of application of meropenem in pharmacotherapy may cause the spread of methyl-β-lactamases.

References

• 1. Bax R.P., Bastain W., Featherstone A., Wilkinson D.M., HutchisonM.: The pharmacokinetics of meropenem in volunteers. J. Antimicrob.Chemother., 1989; 24 (suppl. A): 311-320
  Google Scholar
• 2. Blumer J.L.: Meropenem: evaluation of a new generation carbapenem.Int. J. Antimicrob. Agents., 1997; 8: 73-92
  Google Scholar
• 3. Bradley J.S., Garau J., Lode H., Rolston K.V., Wilson S.E., Quinn J.P.:Carbapenems in clinical practice: a guide to their use in serious infection.Int. J. Antimicrob. Agents, 1999; 11: 93-100
  Google Scholar
• 4. Chambers H.F., Moreau D., Yajko D., Miick C., Wagner C., HackbarthC., Kocagöz S., Rosenberg E., Hadley W.,K., Nikaido H.: Can penicillinsand other β-lactam antibiotics be used to treat tuberculosis? Antimicrob.Agents Chemother., 1995; 39: 2620-2624
  Google Scholar
• 5. Cielecka-Piontek J., Paczkowska M., Krause A., Zalewski P., StróżykM.: Antybiotykoterapia dzieci – wyzwanie dla farmakologa i technologa.Zastosowanie analogów karbapenemu w antybiotykoterapii pediatrycznej.Świat Przemysłu Farmaceutycznego, 2012; 3: 65-67
  Google Scholar
• 6. Clark R.H, Bloom B.T, Spitzer A.R., Gerstmann D.R.: Reported medicationuse in the neonatal intensive care unit: data from a large nationaldata set. Pediatrics, 2006; 117: 1979-1987
  Google Scholar
• 7. Cohen-Wolkowiez M., Poindexter B., Bidegain M., Weitkamp J.H.,Schelonka R.L., Randolph D.A., Ward R.M., Wade K., Valencia G., BurchfieldD., Arrieta A., Mehta V., Walsh M., Kantak A., Rasmussen M. i wsp.:Safety and effectiveness of meropenem in infants with suspected orcomplicated intra-abdominal infections. Clin. Infect. Dis., 2012; 55:1495-1502
  Google Scholar
• 8. Cometta A., Calandra T., Gaya H., Zinner S.H., de Bock R., Del FaveroA., Bucaneve G., Crokaert F., Kern W.V., Klastersky J., Langenaeken I., MicozziA., Padmos A., Paesmans M., Viscoli C., Glauser M.P.: Monotherapywith meropenem versus combination therapy with ceftazidime plusamikacin as empiric therapy for fever in granulocytopenic patients withcancer. Antimicrob. Agents Chemother., 1996; 40: 1108-1115
  Google Scholar
• 9. Cox C.E., Holloway W.J., Geckler R.W.: A multicenter comparativestudy of meropenem and imipenem/cilastatin in the treatment of complicatedurinary tract infections in hospitalized patients. Clin. Infect.Dis., 1995; 21: 86-92
  Google Scholar
• 10. De Luca M., Amodio D., Chiurchiù S., Castelluzzo M.A., Rinelli G., BernaschiP., Calò Carducci F.I., D’Argenio P.: Granulicatella bacteraemia inchildren: two cases and review of the literature. BMC Pediatr., 2013; 13: 61
  Google Scholar
• 11. England K., Boshoff H.I., Arora K., Weiner D., Dayao E., SchimelD., Via L.E., Barry C.E.3rd.: Meropenem-clavulanic acid shows activityagainst Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother.,2012; 56: 3384-3387
  Google Scholar
• 12. Erbey F., Bayram I., Yilmaz S., Tanyeli A.: Meropenem monotherapyas an empirical treatment of febrile neutropenia in childhood cancerpatients. Asian Pac. J. Cancer Prev., 2010; 11: 123-126
  Google Scholar
• 13. Fera M.T., Zummo S., De Sarro A.: In vitro activity studies of doripenemand two other carbapenems tested against Pseudomonas aeruginosaand other non-fermentative bacilli. J. Chemother., 2011; 23: 335-340
  Google Scholar
• 14. Force E., Taberner F., Cabellos C., Ribes S., Doménech A., Tubau F.,Viladrich P.F., Gudiol F.: Evaluation of meropenem alone and combinedwith rifampin in the guinea pig model of pneumococcal meningitis. Eur.J. Clin. Microbiol. Infect. Dis., 2009; 28: 807-811
  Google Scholar
• 15. Fukasawa M., Sumita Y., Harabe E.T., Tanio T., Nouda H., Kohzuki T.,Okuda T., Matsumura H., Sunagawa M.: Stability of meropenem and effectof 1 beta-methyl substitution on its stability in the presence of renaldehydropeptidase I. Antimicrob. Agents Chemother., 1992; 36: 1577-1579
  Google Scholar
• 16. Hamacher J., Vogel F., Lichey J., Kohl F.V., Diwok K., Wendel H., LodeH.: Treatment of acute bacterial exacerbations of chronic obstructivepulmonary disease in hospitalised patients-a comparison of meropenemand imipenem/cilastatin. COPD Study Group. J. Antimicrob. Chemother.,1995; 36 (Suppl. A): 121-133
  Google Scholar
• 17. Harrison M.P., Moss S.R., Featherstone A., Fowkes A.G., SandersA.M., Case D.E.: The disposition and metabolism of meropenem inlaboratory animals and man. J. Antimicrob. Chemother., 1989; 24,Suppl. A: 265-277
  Google Scholar
• 18. Holzgrabe U.: Meropenem-clavulanate: a new strategy for thetreatment of tuberculosis? Chem. Med. Chem., 2009; 4: 1051-1053
  Google Scholar
• 19. Hugonnet J.E., Blanchard J.S.: Irreversible inhibition of the Mycobacteriumtuberculosis β-lactamase by clavulanate. Biochemistry,2007; 46: 11998-12004
  Google Scholar
• 20. Hugonnet J.E., Tremblay L.W., Boshoff H.I., Barry C.E.3rd,Blanchard J.S.: Meropenem-clavulanate is effective against extensivelydrug-resistant Mycobacterium tuberculosis. Science, 2009; 323:1215-1218
  Google Scholar
• 21. Huizinga W.K., Warren B.L., Baker L.W., Valleur P., Pezet D.M.,Hoogkamp-Korstanjep J.A., Karran S.J.: Antibiotic monotherapy withmeropenem in the surgical management of intra-abdominal infections.J. Antimicrob. Chemother., 1995; 36 (Suppl. A): 179-189
  Google Scholar
• 22. Lutsar I., Trafojer U.M., Heath P.T., Metsvaht T., Standing J.,Esposito S., de Cabre V.M., Oeser C., Aboulker J.P.: Meropenem vsstandard of care for treatment of late onset sepsis in children ofless than 90 days of age: study protocol for a randomised controlledtrial. Trials, 2011; 12: 215
  Google Scholar
• 23. Martin-Canal G., Saavedra A., Asensi J.M., Suarez-Zarracina T.,Rodriguez-Guardado A., Bustillo E., Fierer J., Carton J.A., CollazosJ., Asensi V.: Meropenem monotherapy is as effective as and saferthan imipenem to treat brain abscesses. Int. J. Antimicrob. Agents,2010; 35: 301-304
  Google Scholar
• 24. Nairn K., Shepherd G.L., Edwards J.R.: Efficacy of meropenemin experimental meningitis. J. Antimicrob. Chemother., 1995; 36(Suppl. A): 73-84
  Google Scholar
• 25. Norrby S.R.: Neurotoxicity of carbapenem antibiotics: consequencesfor their use in bacterial meningitis. J. Antimicrob. Chemother.,2000; 45: 5-7
  Google Scholar
• 26. Norrby S.R., Newell P.A., Faulkner K.L., Lesky W.: Safety profileof meropenem: International clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother.,1995; 36 (suppl. A): 207-223
  Google Scholar
• 27. Papp-Wallace K.M., Endimiani A., Taracila M.A., Bonomo R.A.:Carbapenems: past, present, and future. Antimicrob. Agents Chemother.,2011; 55: 4943-4960
  Google Scholar
• 28. Pryka R.D., Haig G.M.: Meropenem: a new carbapenem antimicrobial.Ann. Pharmacother., 1994; 28: 1045-1054
  Google Scholar
• 29. Second Meeting of the Subcommittee of the Expert Committeeon the Selection and Use of Essential Medicines Geneva: Use ofcarbapenems in children. 2008
  Google Scholar
• 30. Socha P., Wieczorek P., Jakoniuk P., Żórawski M.: Udział metylo-β-laktamaz w oporności na imipenem i meropenem klinicznychszczepów Pseudomonas aeruginosa i Acinetobacter spp. Wiad. Lekarskie,2008; 61: 30-36
  Google Scholar
• 31. World Health Organization: Multidrug and extensively drugresistantTB (M/XDR-TB): 2010 Global Report on Surveillance andResponse, 2010
  Google Scholar
• 32. World Health Organization: Towards universal access to diagnosisand treatment of multidrug-resistant and extensively drugresistanttuberculosis by 2015: WHO progress report, 2011
  Google Scholar
• 33. World Health Organization: Treatment of tuberculosis. Guidelines,2010
  Google Scholar

Full text